

# Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma

Wouter W. de Herder<sup>a</sup> Bruno Niederle<sup>b</sup> Jean-Yves Scoazec<sup>c</sup> Stanislas Pauwels<sup>d</sup>  
Günter Klöppel<sup>e</sup> Massimo Falconi<sup>f</sup> Dik J. Kwekkeboom<sup>g</sup> Kjell Öberg<sup>h</sup>  
Barbro Eriksson<sup>h</sup> Bertram Wiedenmann<sup>i</sup> Guido Rindi<sup>k</sup> Dermot O'Toole<sup>j</sup>  
Diego Ferone<sup>l</sup> and all other Frascati Consensus Conference participants

<sup>a</sup>Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands;

<sup>b</sup>Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria; <sup>c</sup>Hospices Civils de Lyon, Hôpital Edouard-Herriot Service Central d'Anatomie et Cytologie Pathologiques, Lyon, France; <sup>d</sup>Centre de Médecine Nucléaire, Université Catholique de Louvain, Brussels, Belgium; <sup>e</sup>Department of Pathology, University of Kiel, Kiel, Germany; <sup>f</sup>B Unit of Surgery, Department of Surgery, University of Verona, Verona, Italy;

<sup>g</sup>Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands; <sup>h</sup>Department of Endocrine Oncology, University Hospital, Uppsala, Sweden; <sup>i</sup>Department of Internal Medicine, Division of Hepatology and Gastroenterology, Interdisciplinary Center of Metabolism and Endocrinology, Charité, Campus Virchow Hospital, University for Medicine Berlin, Berlin, Germany; <sup>j</sup>Service de Gastroentérologie-Pancréatologie, Pole des Maladies de l'Appareil Digestif, Hôpital Beaujon, Clichy, France; <sup>k</sup>Department of Pathology and Laboratory Medicine, Università degli Studi, Parma, Italy; <sup>l</sup>Department of Endocrinology, Genoa University, Genoa, Italy

© Free Author Copy – for personal use only

ANY DISTRIBUTION OF THIS ARTICLE WITHOUT WRITTEN CONSENT FROM S. KARGER AG, BASEL IS A VIOLATION OF THE COPYRIGHT.

Written permission to distribute the PDF will be granted against payment of a permission fee, which is based on the number of accesses required. Please contact [permission@karger.ch](mailto:permission@karger.ch)

## Epidemiology and Clinicopathological Features

### Minimal Consensus Statement on Epidemiology

Insulinomas are the most common functioning endocrine tumors of the pancreas, with an estimated incidence of 1–3 per million per year. There is an age-specific incidence peak in the fifth decade of life and the incidence is slightly higher in women than in men. Approximately 10% are multiple, less than 10% can be malignant, and 5–10% are associated with the MEN-1 syndrome. These latter tumors are usually multiple and can be malignant in up to 25% of cases. After initial recognition of the key symptoms, careful laboratory testing, sophisticated imaging and eventually meticulous surgery follows in most cases. It is evident that a multidisciplinary team approach is required [1, 2].

### Histopathology of Insulinomas – General

The WHO classifies functioning endocrine tumors of the pancreas into 3 well-defined categories: [1] well-dif-

ferentiated endocrine tumors, with benign or uncertain behavior at the time of diagnosis; [2] well-differentiated endocrine carcinomas with low-grade malignant behavior, and [3] poorly differentiated endocrine carcinomas, with high-grade malignant behavior. Most insulinomas are classified as well-differentiated endocrine tumors, according to the WHO criteria (WHO 1), but occasionally they belong to the WHO 2 or 3 group [3].

### Minimal Consensus Statements on Histopathology and Genetics – Specific

#### Histopathology

A detailed description of the macroscopic, microscopic and immunohistochemical findings, in order to support the diagnosis of insulinoma and to allow for its correct classification according to the current WHO classification is indispensable. The necessary

**Table 1.** Requirements for the histopathological diagnosis of an insulinoma

Macroscopic evaluation	Microscopic evaluation	Immunohistochemistry
Tumor size (largest diameter)	Mitotic index (expressed as the number of mitoses in 10 HPF)	Chromogranin A expression (yes/no; if yes, % of cells positive) Insulin expression (yes/no; if yes, % of cells positive)
Lymph node metastases (yes/no; if yes, number and location of metastatic lymph nodes)	Angioinvasion (yes/no)	Synaptophysin expression (yes/no; if yes, % of cells positive) Insulin expression (yes/no)
Extra-pancreatic invasion (yes/no)	Perineural invasion (yes/no)	Ki-67 index (expressed in % of cells positive)
Distant metastases (yes/no/unknown)		Insulin expression (yes/no; if yes, % of cells positive)

information is listed in table 1. Evaluation of the mitotic index and Ki67 index is required. Ancillary tests include the immunohistochemical detection of chromogranin A and synaptophysin. The immunohistochemical determination of insulin expression by tumor cells is not absolutely necessary for diagnosis. Some insulinomas do not stain positively for insulin despite the correct diagnosis. This might be caused by the rapid release of insulin from the insulin-producing cells [3]. Cytology is not recommended as a standard diagnostic procedure.

#### Genetics

Germline DNA testing for hereditary tumor syndromes is only recommended in specific situations: a familial history or clinical findings suggesting MEN-1 or von Hippel-Lindau disease (VHL); the presence of multiple tumors; or the demonstration of precursor lesions in the peritumoral pancreatic tissue. Mutation analysis should be performed to test for menin or VHL mutations (following informed consent).

### Diagnostic Procedures: Clinical Assessment with Laboratory Tests, Imaging and Nuclear Medicine

#### Clinical Assessment with Laboratory Tests – General

Hypoglycemic symptoms can be grouped into those resulting from neuroglycopenia (commonly including headache, diplopia, blurred vision, confusion, dizziness, abnormal behavior, lethargy, amnesia, whereas rarely, hypoglycemia may result in seizures and coma) and those resulting from the autonomic nervous system (including sweating, weakness, hunger, tremor, nausea, feelings of warmth, anxiety, and palpitations) [4, 5]. Because symptoms occasionally are not specific and insulinoma can mimic several pathological conditions, a broad differential diagnosis should be considered but major distinction should be made between patients with insulinoma and noninsulinoma pancreatogenous hypoglycemia (NIPHS)

[6]. However, Whipple's triad remains fundamentally sound. This triad consists of:

- 1 Symptoms of hypoglycemia.
- 2 Plasma glucose level  $\leq 2.2$  mmol/l ( $\leq 40$  mg/dl).
- 3 Relief of symptoms with administration of glucose.

#### Minimal Consensus Statements Clinical Assessment – Specific

The diagnosis of insulinoma can be absolutely established using the following 6 tight criteria [4, 5]:

- Documented blood glucose levels  $\leq 2.2$  mmol/l ( $\leq 40$  mg/dl).
- Concomitant insulin levels  $\geq 6$   $\mu$ U/l ( $\geq 36$  pmol/l;  $\geq 3$   $\mu$ U/l by ICMA).
- C-peptide levels  $\geq 200$  pmol/l.
- Proinsulin levels  $\geq 5$  pmol/l.
- $\beta$ -Hydroxybutyrate levels  $\leq 2.7$  mmol/l.
- Absence of sulfonylurea (metabolites) in the plasma and/or urine.

Further controlled testing includes the 72-hour fast, which is the gold standard for establishing the diagnosis of insulinoma [7]. When the patient develops symptoms and the blood glucose levels are  $\leq 2.2$  mmol/l ( $\leq 40$  mg/dl), blood is also drawn for C-peptide, proinsulin and insulin. Failure of appropriate insulin suppression in the presence of hypoglycemia substantiates an autonomously secreting insulinoma [4, 5, 8].

#### Imaging and Nuclear Medicine – General

The spectrum of endogenous hyperinsulinism not only includes insulinoma, but also NIPHS/nesidioblastosis. Nesidioblastosis affects approximately 4% of adults with hyperinsulinemic hypoglycemia [9]. The role of imaging is first to detect and provide precise anatomical localization and second to stage the tumor prior to surgery. Insulinomas are usually solitary and the majority is intra-pancreatic in location. They are characteristically small with ap-

proximately two thirds being  $\leq 2$  cm at presentation, making them notoriously difficult to localize radiologically. What is the ideal imaging modality for insulinoma evaluation? The three most useful modalities are: gadolinium-enhanced dynamic magnetic resonance imaging (MRI); 3-phase computed tomography (CT), and endoscopic ultrasound. Invasive techniques such as selective celiac and mesenteric arteriography, venography and venous sampling are progressively being abandoned, and together with somatostatin receptor imaging and positron emission tomography (PET) with  $^{11}\text{C}$ -5-hydroxytryptophan (5-HTP) as tracer (HTP-PET) or  $^{11}\text{C}$ -I-DOPA (DOPA-PET) should be considered as complementary techniques for specific indications. A strikingly wide discrepancy with regard to the results for localization between different centers for each of these techniques presumably reflects the specialist expertise and the availability of equipment. Still, no single modality is 100% effective. Any proposed imaging algorithm should take into account cost, sensitivity, availability and local expertise [1].

### *Minimal Consensus Statements on Imaging and Nuclear Medicine – Specific*

#### *Transabdominal Ultrasound*

Like in many other abdominal disorders, transabdominal ultrasound yields the widest range of success and failure of all preoperative localization tests. It is noninvasive, free of radiation exposure, readily available, relatively inexpensive, and anatomically precise. Key major drawbacks include its extreme dependence on operator expertise and limitations based on patient habitus, which usually is unfavorable in this setting since most of insulinoma patients are obese.

#### *Computed Tomography (CT)*

As the majority of benign insulinomas tend to be small at presentation and, therefore, seldom alter the contour of the pancreas, 3-phase CT should be used to maximize detection. Insulinomas are typically hypervascular and their appearance is that of a hyperattenuating lesion in both the arterial and portal venous phases. Liver metastases also tend to be hypervascular and, therefore, the arterial phase shows the number and size of liver metastases better than the venous phase. Spread to regional nodes is best seen during the arterial phase. The reported sensitivity of CT for the detection of insulinomas is in the range of 30–85%, depending on tumor size [10]. Combined 3-phase CT and endoscopic ultrasound may further increase this sensitivity up to 100% [11].

#### *Magnetic Resonance Imaging (MRI)*

MRI techniques have reported high sensitivities, ranging from 85 to 95%, in the detection of insulinomas and for determining the presence of metastatic disease. As compared to CT, MRI is superior in the detection of small lesions. The enhancement pattern of these tumors on MRI is due primarily to their hypervascularity. Insulinomas are low in signal intensity on fat-

suppressed  $T_1$ -weighted images and moderately high in signal intensity on fat-suppressed  $T_2$ -weighted images, although variations do exist. Small metastases, like the primary tumor, exhibit homogenous enhancement [12–16].

#### *Endoscopic Ultrasound*

In experienced hands, endoscopic ultrasound (EUS) is currently considered the best preoperative procedure to localize insulinomas with a reported sensitivity of 94%. The high spatial resolution of this technique allows the detection of very small lesions and their precise anatomical localization. The sensitivity of this technique is the highest for lesions located in the head and body of the pancreas as compared to localization in the tail. Combined with 3-phase CT, the sensitivity rises to 100%. Endoscopic ultrasound imaging is also able to identify patients that qualify for laparoscopic, minimal invasive surgery [17, 18].

#### *Angiography*

Angiography combined with calcium stimulation and transhepatic portal venous sampling (THPVS) previously was considered the gold standard of insulinoma localization [19]. Angiography combines both anatomic localization of a tumor with functional information provided by THPVS, which can confirm that a visualized angiographic abnormality is an insulinoma. Additionally, in the instance in which the angiogram fails to demonstrate the tumor, THPVS will still be able to localize the tumor to a particular region of the pancreas [19]. Noninvasive imaging techniques have evolved such that angiography and THPVS should today be considered only for problem cases [19].

#### *Intraoperative Ultrasound*

Intraoperative ultrasound (IOUS) has been highly useful in localizing these small tumors. Additionally, it demonstrates the relevant operative anatomy, defining the relationship of the tumor to the pancreatic and bile ducts, and adjacent blood vessels. Intraoperative localization techniques, which include both careful palpation of the pancreas and the use of IOUS, remain the most reliable way to localize insulinomas, and to determine the correct surgical procedure (enucleation vs. middle pancreatectomy). Moreover, it is mandatory in patients in whom multiple lesions are suspected [20, 21].

#### *Laparoscopic Intraoperative Ultrasound*

Laparoscopic IOUS in experienced hands can identify >85% of insulinomas [22, 23].

#### *$^{111}\text{In}$ -Pentetreotide Scintigraphy*

$^{111}\text{In}$ -pentetreotide scintigraphy is only positive in 46% of benign insulinomas because not all insulinomas express somatostatin receptor subtypes that bind  $^{111}\text{In}$ -pentetreotide. In malignant insulinomas, the relative distribution of somatostatin receptor subtypes is different from benign tumors and a higher rate of scan-positivity with this technique can be expected [24–26].

#### *Positron Emission Tomography*

The results of  $^{18}\text{F}$ -fluorodeoxyglucose ( $^{18}\text{F}$ -FDG) PET imaging of insulinomas are disappointing, presumably because of their low proliferative potential. Promising results, however, have been obtained using  $^{11}\text{C}$ -5-HTP,  $^{18}\text{F}$ -DOPA, and  $^{67}\text{Ga}$ -DOTA-DPhe $^1$ -Tyr $^3$ -octreotide ( $^{67}\text{Ga}$ -DOTATOC) [27, 28].

## Surgical Therapy

### *Minimal Consensus Statements on Surgery*

During operation, the entire pancreas is explored. In the presence of the MEN-1 genotype, multiple tumors have to be excluded. Tumor enucleation is preferred. When the tumor is located in the neck, body, or tail of the pancreas and is anatomically unsuitable for enucleation, central or distal pancreatectomy are safe and effective alternatives [29]. Blind distal resections in search of an occult insulinoma are not recommended anymore. In specific cases laparoscopic surgery seems feasible [23, 30].

## Medical Therapy

### *Medical Therapy – General*

Dietary management is designed to prevent prolonged periods of fasting. Medical management is reserved only for patients who are unable or unwilling to undergo surgical treatment, for preoperative control of blood glucose levels or for unresectable metastatic disease.

### *Minimal Consensus Statements on Medical Therapy – Specific*

Diazoxide (50–300 mg/day, can be increased up to 600 mg/day) suppresses insulin secretion by direct action on the beta cells and by enhancing glycogenolysis [31]. Diazoxide is the most effective drug for controlling hypoglycemia. However, side effects are: edema, weight gain, renal impairment, and hirsutism. Verapamil and diphenylhydantoin have also been reported to be successful in the control of hypoglycemia [32–34]. In refractory cases, glucocorticoids such as prednisolone can be effective as well. Somatostatin analogs like octreotide and lanreotide can be useful in preventing hypoglycemia in those patients with somatostatin receptor subtype 2-positive tumors, but can worsen hypoglycemia in those patients with tumors that do not express this receptor subtype [35, 36]. Interferon-alpha has been shown to be beneficial in selected cases [37].

### *Minimal Consensus Statements on Malignant Insulinomas Management*

Malignant insulinomas account for only about 5–10% of all insulinomas. The primaries are usually single and generally larger than benign insulinomas. The median disease-free survival after curative resection is 5 years, but recurrence occurs in more than 60% at a median interval of 2.5–3 years. Median survival with recurrent tumors is less than 2 years [38]. Palliative resection may prolong median survival. When surgical options to address malignancy have been exhausted, other debulking procedures such as radiofrequency thermoablation, cryotherapy, hepatic ar-

tery embolization and chemoembolization, and peptide receptor radionuclide therapy have been utilized, yielding good, but regrettably only temporary, palliation [39, 40]. Systemic chemotherapeutic options include combinations of doxorubicin and streptozocin, which can result in a significant (up to >60%) tumor regression rate, and remission from hypoglycemic symptoms can be extended up to 1.5 years [41].

## List of Participants

H. Ahlman, Department of Surgery, Gothenburg University, Gothenburg (Sweden); R. Arnold, Department of Gastroenterology, Philipps University, Marburg (Germany); W.O. Bechstein, Department of Surgery, Johann-Wolfgang-Goethe-Universität, Frankfurt (Germany); G. Cadiot, Department of Hepatology and Gastroenterology, CHU Bichat – B. Claude Bernard University, Paris (France); M. Caplin, Department of Gastroenterology, Royal Free Hospital, London (UK); E. Christ, Department of Endocrinology, Inselspital, Bern (Switzerland); D. Chung, Department of Gastroenterology, Massachusetts General Hospital, Boston, Mass. (USA); A. Couvelard, Department of Gastroenterology, Beaujon Hospital, Clichy (France); G. Delle Fave, Department of Digestive and Liver Disease, Ospedale S. Andrea, Rome (Italy); A. Falchetti, Department of Internal Medicine, University of Florence and Centro di Riferimento Regionale Tumori Endocrini Ereditari, Azienda Ospedaliera Careggi, Florence (Italy); P. Goetzki, Department of Surgery, Städtisches Klinikum Neuss, Lukas Hospital, Neuss (Germany); D. Gross, Department of Endocrinology and Metabolism, Hadassah University, Jerusalem (Israel); D. Hochhauser, Department of Oncology, Royal Free University, London (UK); R. Hyrdel, Department of Internal Medicine, Martin University, Martin (Slovakia); R. Jensen, Department of Cell Biology, National Institute of Health, Bethesda, Md. (USA); G. Kaltsas, Department of Endocrinology and Metabolism, Genimatas Hospital, Athens (Greece); F. Keleştimur, Department of Endocrinology, Erciyes University, Kayseri (Turkey); R. Kianmanesh, Department of Surgery, UFR Bichat-Beaujon-Louis Mourier Hospital, Colombes (France); W. Knapp, Department of Nuclear Medicine, Medizinische Hochschule Hannover, Hannover (Germany); U.P. Knigge, Department of Surgery, Rigshospitalet Blegdamsvej Hospital, Copenhagen (Denmark); P. Komminoth, Department of Pathology, Kantonsspital, Baden (Switzerland); M. Körner, University of Bern, Institut für Pathologie, Bern (Switzerland); B. Kos-Kudła, Department of Endocrinology, Slaska University, Zabrze (Poland); L. Kvols, Department of Oncology, South Florida University, Tampa, Fla. (USA); V. Lewington, Department of Radiology, Royal Marsden Hospital, Sutton (UK); J.M. Lopes, Department of Pathology, IPATIMUP Hospital, Porto (Portugal); R. Manfredi, Department of Radiology, Istituto di Radiologia, Policlinico GB, Verona (Italy); A.M. McNicol, Department of Oncology and Pathology, Royal Infirmary Hospital, Glasgow (UK); E. Mitry, Department of Hepatology and Gastroenterology, CHV A Pare Hospital, Boulogne (France); G. Nikou, Department of Propaedeutic Internal Medicine, Laiko Hospital, Athens (Greece); O. Nilsson, Department of Pathology, Gothenberg University, Gothenberg (Sweden); J. O'Connor, Department of Oncology, Alexander Fleming Institute, Buenos Aires (Argentina); U.-F. Pape, Department of Inter-

nal Medicine, Charité, University of Berlin (Germany); M. Pavel, Department of Endocrinology, Erlangen University, Erlangen (Germany); A. Perren, Department of Pathology, Universitätsspital Zürich, Zürich (Switzerland); U. Plöckinger, Department of Hepatology and Gastroenterology, Charité Universitätsmedizin, Berlin (Germany); J. Ramage, Department of Gastroenterology, North Hampshire Hospital, Hampshire (United Kingdom); J. Ricke, Department of Radiology, Charité Universitätsmedizin, Berlin (Germany); P. Ruzsiewicz, Department of Gastroenterology, Beaujon Hospital, Clichy (France); R. Salazar, Department of Oncology, Institut Català d'Oncologia, Barcelona (Spain); A. Sauvanet, Department of Surgery, Beaujon Hospital, Clichy (France); A. Scarpa, Department of Pathology, Verona University, Verona

(Italy); M.I. Sevilla Garcia, Department of Oncology, Virgen de la Victoria Hospital, Malaga (Spain); T. Steinmüller, Department of Surgery, Vivantes Humboldt Hospital, Berlin (Germany); A. Sundin, Department of Radiology, Uppsala University, Uppsala (Sweden); B. Taal, Department of Oncology, Netherlands Cancer Centre, Amsterdam (the Netherlands); E. Van Cutsem, Department of Gastroenterology, Gasthuisberg University, Leuven (Belgium); M.P. Vullierme, Department of Gastroenterology, Beaujon Hospital, Clichy (France); S. Wildi, Department of Surgery, Zürich Hospital, Zürich (Switzerland); J.C. Yao, Department of Oncology, University of Texas, Houston, Tex. (USA); S. Zgliczyński, Department of Endocrinology, Bielanski Hospital, Warsaw (Poland).

## References

- Grant CS: Insulinoma. *Best Pract Res Clin Gastroenterol* 2005;19:783–798.
- de Herder WW: Insulinoma. *Neuroendocrinology* 2004;80(suppl 1):20–2–20–22.
- Rindi G, Kloppel G: Endocrine tumors of the gut and pancreas tumor biology and classification. *Neuroendocrinology* 2004;80(suppl 1):12–5–12–15.
- Service FJ: Insulinoma and other islet-cell tumors. *Cancer Treat Res* 1997;89:335–346.
- Service FJ: Hypoglycemic disorders. *N Engl J Med* 1995;332:1144–1152.
- Service FJ, Natt N, Thompson GB, et al: Non-insulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. *J Clin Endocrinol Metab* 1999;84:1582–1589.
- Service FJ, Natt N: The prolonged fast. *J Clin Endocrinol Metab* 2000;85:3973–3974.
- Service FJ, Dale AJ, Elveback LR, Jiang NS: Insulinoma: clinical and diagnostic features of 60 consecutive cases. *Mayo Clin Proc* 1976;51:417–429.
- Anlauf M, Wieben D, Perren A, et al: Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of beta-cell changes. *Am J Surg Pathol* 2005;29:524–533.
- Noone TC, Hosey J, Firat Z, Semelka RC: Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. *Best Pract Res Clin Endocrinol Metab* 2005;19:195–211.
- Gouya H, Vignaux O, Augui J, et al: CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. *Am J Roentgenol* 2003;181:987–992.
- Semelka RC, Custodio CM, Cem BN, Woosley JT: Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. *J Magn Reson Imaging* 2000;11:141–148.
- Pamuklar E, Semelka RC: MR imaging of the pancreas. *Magn Reson Imaging Clin N Am* 2005;13:313–330.
- Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB: Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. *Radiology* 2000;214:483–490.
- Owen NJ, Sohaib SA, Peppercorn PD, et al: MRI of pancreatic neuroendocrine tumours. *Br J Radiol* 2001;74:968–973.
- Catalano C, Pavone P, Laghi A, et al: Localization of pancreatic insulinomas with MR imaging at 0.5 T. *Acta Radiol* 1999;40:644–648.
- Kann PH, Rothmund M, Zielke A: Endoscopic ultrasound imaging of insulinomas: limitations and clinical relevance. *Exp Clin Endocrinol Diabetes* 2005;113:471–474.
- McLean AM, Fairclough PD: Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. *Best Pract Res Clin Endocrinol Metab* 2005;19:177–193.
- Jackson JE: Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. *Best Pract Res Clin Endocrinol Metab* 2005;19:229–239.
- Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA: Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025–1026. *Arch Surg* 2001;136:1020–1025.
- Norton JA: Intraoperative methods to stage and localize pancreatic and duodenal tumors. *Ann Oncol* 1999;10(suppl 4):182–184.
- Grover AC, Skarulis M, Alexander HR, et al: A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. *Surgery* 2005;138:1003–1008.
- Berends FJ, Cuesta MA, Kazemier G, et al: Laparoscopic detection and resection of insulinomas. *Surgery* 2000;128:386–391.
- Vezzosi D, Bennet A, Rochaix P, et al: Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. *Eur J Endocrinol* 2005;152:757–767.
- Krenning EP, Kwekkeboom DJ, Bakker WH, et al: Somatostatin receptor scintigraphy with [<sup>111</sup>In-DTPA-D-Phe1]- and [<sup>123</sup>I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. *Eur J Nucl Med* 1993;20:716–731.
- Bertherat J, Tenenbaum F, Perlemoine K, et al: Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. *J Clin Endocrinol Metab* 2003;88:5353–5360.
- Orlefors H, Sundin A, Garske U, et al: Whole-body <sup>11</sup>C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. *J Clin Endocrinol Metab* 2005;90:3392–3400.
- Eriksson B, Orlefors H, Oberg K, Sundin A, Bergstrom M, Langstrom B: Developments in PET for the detection of endocrine tumours. *Best Pract Res Clin Endocrinol Metab* 2005;19:311–324.
- Aranha GV, Shoup M: Nonstandard pancreatic resections for unusual lesions. *Am J Surg* 2005;189:223–228.
- Kaczirek K, Asari R, Scheuba C, Niederle B: Organic hyperinsulinism and endoscopic surgery. *Wien Klin Wochenschr* 2005;117:19–25.
- Stabile BE: Islet cell tumors. *Gastroenterologist* 1997;5:213–232.
- Stehouwer CD, Lems WF, Fischer HR, Hackeng WH: Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201-995) more effective than single therapy with either drug? *Neth J Med* 1989;35:86–94.
- Cohen MS, Bower RH, Fidler SM, Johnsonbaugh RE, Sode J: Inhibition of insulin release by diphenylhydantoin and diazoxide in a patient with benign insulinoma. *Lancet* 1973;ii:40–41.

- 34 Brodows RG, Campbell RG: Control of refractory fasting hypoglycemia in a patient with suspected insulinoma with diphenylhydantoin. *J Clin Endocrinol Metab* 1974;38:159-162.
- 35 Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ: Octreotide. *N Engl J Med* 1996;334:246-254.
- 36 Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA: Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (sandostatin). *Acta Endocrinol (Copenh)* 1989;121:34-40.
- 37 Eriksson B, Oberg K, Alm G, et al: Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. *Lancet* 1986;ii:1307-1309.
- 38 Danforth DN Jr, Gorden P, Brennan MF: Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. *Surgery* 1984;96:1027-1037.
- 39 Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al: Radiolabeled somatostatin analog [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate in patients with endocrine gastroenteropancreatic tumors. *J Clin Oncol* 2005;23:2754-2762.
- 40 O'Toole D, Maire F, Ruzsniwski P: Ablative therapies for liver metastases of digestive endocrine tumours. *Endocr Relat Cancer* 2003;10:463-468.
- 41 Rougier P, Mitry E: Chemotherapy in the treatment of neuroendocrine malignant tumors. *Digestion* 2000;62(suppl 1):73-8-73-78.